Rocket Pharmaceuticals, Inc.

DB:9IP1 Stock Report

Market Cap: €623.1m

Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:9IP1 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Apr 25Sell€4,477John MilitelloIndividual718€6.24
10 Apr 25Buy€90,841Gaurav ShahIndividual20,000€4.54
09 Apr 25Buy€89,725Kinnari PatelIndividual21,099€4.25
04 Apr 25Sell€36,090Aaron OndreyIndividual7,489€4.82
25 Feb 25Sell€65,819Jonathan SchwartzIndividual6,532€10.08
21 Feb 25Sell€32,616Martin WilsonIndividual3,222€10.12
21 Feb 25Sell€165,034Gaurav ShahIndividual16,303€10.12
21 Feb 25Sell€27,706John MilitelloIndividual2,737€10.12
21 Feb 25Sell€61,527Kinnari PatelIndividual6,078€10.12
23 Jan 25Sell€8,933John MilitelloIndividual896€9.97
21 Nov 24Sell€138,021Gaurav ShahIndividual11,091€12.44
21 Nov 24Sell€14,622Martin WilsonIndividual1,175€12.44
21 Nov 24Sell€15,232John MilitelloIndividual1,224€12.44
21 Nov 24Sell€57,095Kinnari PatelIndividual4,588€12.44
21 Nov 24Sell€147,625Jonathan SchwartzIndividual8,561€22.26
31 Oct 24Sell€14,041John MilitelloIndividual917€15.31
31 Oct 24Sell€47,160Mark WhiteIndividual3,080€15.31
16 Aug 24Sell€67,155Kinnari PatelIndividual3,989€16.83
16 Aug 24Sell€17,289Martin WilsonIndividual1,027€16.83
16 Aug 24Sell€162,457Gaurav ShahIndividual9,650€16.83
16 Aug 24Sell€17,912John MilitelloIndividual1,064€16.83
22 Jul 24Sell€17,171John MilitelloIndividual812€21.15
08 Jul 24Sell€56,963Mark WhiteIndividual3,026€18.82

Insider Trading Volume

Insider Buying: 9IP1 insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of 9IP1?
Owner TypeNumber of SharesOwnership Percentage
Private Companies104,9270.095%
Individual Insiders2,604,3952.36%
Hedge Funds23,234,94721%
Institutions84,536,61376.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.

Top Shareholders

Top 25 shareholders own 76.26% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.4%
RTW Investments, LP
17,687,772€102.3m0%1.74%
6.75%
BlackRock, Inc.
7,274,190€42.1m2.49%no data
6.64%
Wellington Management Group LLP
7,151,721€41.4m-43.4%0.01%
6.14%
The Vanguard Group, Inc.
6,617,784€38.3m0.61%no data
5.15%
Maverick Capital, Ltd.
5,547,175€32.1m6.69%0.59%
4.47%
Westfield Capital Management Company, L.P.
4,820,701€27.9m2.25%0.14%
3.44%
State Street Global Advisors, Inc.
3,705,461€21.4m7.15%no data
3.25%
Suvretta Capital Management, LLC
3,502,000€20.3m36.4%0.93%
3.05%
Janus Henderson Group plc
3,290,843€19.0m-17.8%0.01%
2.83%
T. Rowe Price Group, Inc.
3,043,682€17.6m-3.33%no data
1.87%
Morgan Stanley, Investment Banking and Brokerage Investments
2,018,589€11.7m118%no data
1.85%
Geode Capital Management, LLC
1,994,044€11.5m13.8%no data
1.5%
MPM BioImpact LLC
1,618,265€9.4m58.6%1.73%
1.48%
Point72 Asset Management, L.P.
1,598,264€9.2m0%0.02%
1.4%
Citadel Advisors LLC
1,509,004€8.7m-63.4%0.01%
1.37%
Prosight Management, LP
1,480,000€8.6m35.9%3.16%
1.22%
Pictet Asset Management Limited
1,317,969€7.6m0%0.01%
1.02%
Novo Holdings A/S
1,100,000€6.4m0%0.01%
1.02%
Cowen Inc,Private Banking and Investment Banking Investments
1,100,000€6.4m0%0.4%
1.02%
Baker Bros. Advisors LP
1,097,079€6.3m1,030%0.06%
1%
Frazier Life Sciences Management, LP
1,079,025€6.2m-27%0.32%
0.95%
Gaurav Shah
1,020,631€5.9m-13.4%no data
0.8%
Putnam LLC
866,789€5.0m35.4%no data
0.8%
Medical Strategy GmbH, Asset Management Arm
865,131€5.0m0%0.4%
0.79%
Tang Capital Management, LLC
850,000€4.9m13.3%0.28%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 17:42
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity